Overview

Safety and Efficacy Study of VIS649 for IgA Nephropathy

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
Phase:
Phase 2
Details
Lead Sponsor:
Visterra, Inc.
Treatments:
Antibodies
Immunoglobulin A
Immunoglobulins